[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to analyze the clinical presentation and diagnosis.\n\nThe patient presents with:\n- Muscle weakness and palpitations\n- Physical features: low-set ears, micrognathia, and clinodactyly\n- ECG findings: frequent PVCs, prolonged QTc (490 ms), prominent U waves\n- Confirmed KCNJ2 mutation\n- Continued non-sustained VT despite beta-blocker therapy\n\nThis clinical picture is consistent with Andersen-Tawil Syndrome (ATS), also known as Long QT Syndrome type 7. ATS is characterized by the triad of periodic paralysis, cardiac arrhythmias, and distinctive physical features. The KCNJ2 gene mutation affects potassium channels.\n\nFor pharmacologic management of arrhythmias in ATS:\n- Beta-blockers (like nadolol) are first-line but have already failed in this patient\n- Class IC antiarrhythmics (flecainide) are contraindicated in channelopathies with structural abnormalities\n- Amiodarone has significant long-term toxicity concerns in young patients\n- Verapamil is not typically effective for ventricular arrhythmias in ATS\n- Mexiletine, a Class IB sodium channel blocker, has shown efficacy in suppressing ventricular arrhythmias in Andersen-Tawil Syndrome and can shorten the QT interval\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to analyze the clinical presentation and diagnostic findings.\n\nThe patient presents with:\n- Bone pain and exophthalmos\n- \"Hairy kidney\" appearance on CT (characteristic of Erdheim-Chester disease)\n- Osteosclerotic bone lesions\n- Foamy histiocytes that are CD68+ and CD1a- on biopsy\n- BRAF V600E mutation\n\nThese findings are consistent with Erdheim-Chester disease (ECD), a rare non-Langerhans cell histiocytosis. The key diagnostic features include:\n1. The \"hairy kidney\" appearance due to perinephric infiltration\n2. Osteosclerotic bone lesions\n3. CD68+ and CD1a- histiocytes (distinguishing it from Langerhans cell histiocytosis)\n4. BRAF V600E mutation (present in >50% of ECD cases)\n\nFor treatment:\n- Vemurafenib is a BRAF inhibitor specifically targeting the BRAF V600E mutation\n- Rituximab is a CD20 antibody used for B-cell disorders\n- High-dose prednisone alone is not the standard treatment for BRAF+ ECD\n- Methotrexate is used in some histiocytic disorders but not first-line for BRAF+ ECD\n- Infliximab is a TNF inhibitor not typically used for ECD\n\nGiven the presence of the BRAF V600E mutation, the most appropriate targeted therapy would be vemurafenib.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the relationship between Acute Fatty Liver of Pregnancy (AFLP) and potential neonatal complications.\n\nAFLP is associated with fetal long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, which is a disorder of fatty acid oxidation. This genetic disorder can be inherited by the infant and can cause sudden death in the neonatal period if undiagnosed.\n\nThe most appropriate screening test to identify this condition in the neonate would be a plasma acylcarnitine profile. This test can detect abnormal patterns of acylcarnitines that are characteristic of fatty acid oxidation disorders, including LCHAD deficiency.\n\n- Option A (Serum ammonia and lactate): While these may be elevated in metabolic disorders, they are not specific for fatty acid oxidation disorders.\n- Option B (Plasma acylcarnitine profile): This is the most specific test for identifying fatty acid oxidation disorders like LCHAD deficiency.\n- Option C (Galactose-1-phosphate uridyltransferase): This tests for galactosemia, not relevant to AFLP.\n- Option D (Very long-chain fatty acids): This tests primarily for peroxisomal disorders, not mitochondrial fatty acid oxidation disorders.\n- Option E (Hemoglobin electrophoresis): This tests for hemoglobinopathies, not relevant to AFLP.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To address this case, I need to analyze the key clinical features and complications:\n\n1. Patient has G6PD deficiency and HIV\n2. Developed methemoglobinemia (25%) after dapsone administration\n3. Was incorrectly given methylene blue, which is contraindicated in G6PD deficiency\n4. Now has acute hemolysis and worsening hypoxia\n\nMethylene blue is contraindicated in G6PD deficiency because it can cause severe hemolysis, which has occurred in this patient. Repeating methylene blue (Option A) would worsen the hemolysis.\n\nHigh-dose Ascorbic Acid (Option B) can reduce methemoglobin but works slowly and is insufficient for this severe, deteriorating case.\n\nExchange transfusion (Option C) is the most appropriate intervention as it will:\n- Remove methemoglobin-containing RBCs\n- Remove the hemolytic trigger (dapsone and methylene blue)\n- Replace with normal RBCs to improve oxygen-carrying capacity\n- Address both the methemoglobinemia and acute hemolysis\n\nHyperbaric oxygen (Option D) may help with tissue oxygenation but doesn't address the hemolysis.\n\nHydroxocobalamin (Option E) is not a standard treatment for methemoglobinemia or hemolysis.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the genetic defect most consistent with this presentation, I'll analyze the clinical features and laboratory findings.\n\nThe patient presents with:\n- Generalized erythroderma (widespread skin redness)\n- Lymphadenopathy (enlarged lymph nodes)\n- Hepatosplenomegaly (enlarged liver and spleen)\n- Chronic diarrhea\n- Eosinophilia and lymphocytosis\n- Absence of B cells\n- Elevated numbers of oligoclonal, activated T cells\n\nThis clinical picture is most consistent with Omenn syndrome, which is characterized by erythroderma, lymphadenopathy, hepatosplenomegaly, eosinophilia, elevated IgE, and absence of B cells with oligoclonal T cell expansion. Omenn syndrome is caused by hypomorphic (partial loss-of-function) mutations in RAG1 or RAG2 genes, which are involved in V(D)J recombination necessary for T and B cell receptor development.\n\nOption A (BTK mutation) causes X-linked agammaglobulinemia with absent B cells but normal T cells.\nOption C (CD40 Ligand mutation) causes X-linked hyper-IgM syndrome with normal B cell numbers.\nOption D (STAT3 mutation) causes Hyper-IgE syndrome (Job syndrome).\nOption E (WAS gene mutation) causes Wiskott-Aldrich syndrome with thrombocytopenia.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to identify the characteristic Doppler flow pattern in ALCAPA.\n\nIn ALCAPA, the left coronary artery abnormally originates from the pulmonary artery instead of the aorta. This creates a pathological flow pattern because:\n\n1) Initially, antegrade flow occurs from the pulmonary artery into the left coronary artery\n2) As pulmonary vascular resistance drops after birth, the pressure in the pulmonary artery becomes lower than systemic pressure\n3) Collaterals develop between the right and left coronary systems\n4) This leads to retrograde flow in the left coronary artery, with blood flowing from the left coronary artery back into the pulmonary artery (coronary steal)\n\nOn color Doppler, the pathognomonic finding in ALCAPA is retrograde flow from the left coronary artery into the pulmonary artery. This represents the \"coronary steal\" phenomenon where oxygenated blood from the right coronary artery flows through collaterals to the left coronary artery and then abnormally drains into the low-pressure pulmonary artery instead of perfusing the myocardium.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine the most appropriate treatment, I need to analyze the clinical presentation and diagnostic findings.\n\nThe patient has:\n- Nephrotic syndrome\n- Low serum C3, normal C4\n- C3-dominant staining on immunofluorescence\n- Membranoproliferative pattern on light microscopy\n- Negative serum protein electrophoresis\n- Abnormal kappa:lambda ratio of 5.0 (normal is 0.26-1.65)\n\nThis presentation is consistent with C3 glomerulopathy with an underlying monoclonal gammopathy. The elevated kappa:lambda ratio indicates a monoclonal process despite negative SPEP. This is likely a case of monoclonal gammopathy of renal significance (MGRS).\n\nIn MGRS with C3 glomerulopathy features, the underlying B-cell or plasma cell clone produces a monoclonal protein that activates the alternative complement pathway, leading to C3-dominant deposition.\n\nTreatment options:\nA. Eculizumab - While useful in some C3 glomerulopathies, it doesn't address the underlying monoclonal process\nB. Mycophenolate Mofetil - Immunosuppressive that doesn't target the underlying clone\nC. Clone-directed chemotherapy - Targets the underlying B-cell/plasma cell clone producing the pathogenic monoclonal protein\nD. High-dose steroids alone - Insufficient for MGRS\nE. Plasma exchange - Temporary removal of circulating proteins without addressing production\n\nThe most appropriate treatment is to target the underlying clone producing the pathogenic protein.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the ventilator pattern described.\n\nThe scenario describes:\n- A patient on AC-VC mode who is deeply sedated but not paralyzed\n- A time-triggered mandatory breath occurs first\n- This is followed by a drop in esophageal pressure (indicating diaphragmatic contraction)\n- This diaphragmatic contraction occurs during the inspiratory phase\n- It triggers a second breath during exhalation, causing breath stacking\n\nThis pattern describes reverse triggering, which is a phenomenon where the ventilator-delivered breath triggers a reflexive diaphragmatic contraction. It's essentially a patient-ventilator dyssynchrony where the mechanical breath stimulates the patient's respiratory center to contract the diaphragm.\n\nUnlike double triggering from flow starvation (which would be patient-initiated), this begins with a time-triggered breath. It's not ineffective triggering (where patient effort fails to trigger a breath), not premature cycling (early termination of inspiration), and not auto-triggering (where breaths are triggered without patient effort).\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to analyze the clinical scenario and laboratory findings.\n\nThe patient is a 28-year-old woman who is 3 months postpartum with bleeding symptoms. Her labs show:\n- Prolonged aPTT (78s)\n- Normal PT (12s)\n- Mixing study that fails to correct the aPTT (suggests an inhibitor)\n- Factor VIII activity <1%\n\nThis presentation is consistent with acquired hemophilia A, which can occur postpartum. The key features are:\n1. Isolated prolonged aPTT\n2. Very low factor VIII activity\n3. Failure of mixing study to correct (indicating presence of an inhibitor)\n4. Postpartum timing (a known risk factor for acquired hemophilia)\n\nFor acute bleeding control in acquired hemophilia A with high-titer inhibitors:\n- Desmopressin (DDAVP) is ineffective when FVIII is this low\n- Cryoprecipitate contains FVIII but would be neutralized by the inhibitor\n- Recombinant Human Factor VIII would likely be neutralized by the inhibitor\n- Recombinant Porcine Factor VIII is less likely to be neutralized by human FVIII inhibitors\n- Prednisone is used for long-term inhibitor eradication but not acute bleeding control\n\nFor acute bleeding in acquired hemophilia A, bypassing agents (recombinant FVIIa or activated prothrombin complex concentrate) would be ideal, but among the options given, recombinant porcine FVIII is most appropriate as it's less recognized by human FVIII inhibitors.\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Based on the clinical scenario, this patient likely has Plasmodium knowlesi infection, which is endemic in Malaysian Borneo. P. knowlesi can cause severe disease similar to P. falciparum but microscopically resembles P. malariae with band forms. The key distinguishing feature of P. knowlesi's replication cycle is its 24-hour erythrocytic cycle (quotidian fever pattern), which is shorter than P. falciparum's 48-hour cycle.\n\nP. knowlesi has the shortest erythrocytic cycle of all human malaria parasites, completing its asexual reproduction every 24 hours, which explains the daily (quotidian) fevers described in the case. P. falciparum has a 48-hour cycle, P. vivax and P. ovale have 48-hour cycles, and P. malariae has a 72-hour cycle. P. knowlesi also preferentially invades younger red blood cells but not specifically reticulocytes like P. vivax, and it does not have a hypnozoite stage.\n\nThe answer is (A)"}]